{"id":"NCT01753557","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C","officialTitle":"A Phase 3 Study of MP-424 in Combination With PEG-IFN Alfa-2a and RBV, in Subjects With Genotype 1 Hepatitis C, Who Are Treatment-Naïve or Relapsed After Previous Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12","primaryCompletion":"2014-11","completion":"2014-11","firstPosted":"2012-12-20","resultsPosted":"2016-10-03","lastUpdate":"2016-10-03"},"enrollment":54,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C (CHC)"],"interventions":[{"type":"DRUG","name":"MP-424","otherNames":[]},{"type":"DRUG","name":"RBV","otherNames":[]},{"type":"DRUG","name":"PEG-IFN alfa-2a","otherNames":[]}],"arms":[{"label":"Treatment-Naive","type":"EXPERIMENTAL"},{"label":"Treatment-Relapsed","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of MP-424 with PEG-IFN Alfa-2a and RBV in patients with genotype 1 hepatitis C, who are naïve to its treatment or relapsed after previous treatment.","primaryOutcome":{"measure":"Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)","timeFrame":"48 weeks","effectByArm":[{"arm":"Treatment-Naive","deltaMin":85.7,"sd":null},{"arm":"Treatment-Relapsed","deltaMin":94.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["27062488"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":35},"commonTop":["Anaemia","White blood cell count decreased","Platelet count decreased","Pyrexia","Malaise"]}}